{
    "nctId": "NCT00054028",
    "briefTitle": "Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer",
    "officialTitle": "A Phase I/II Study of Suramin in Combination With Paclitaxel in Advanced (Stage IIIB or IV) Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "Percentage of Patients That Achieved Target Suramin Concentrations in Plasma",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have histologically or cytologically confirmed stage IIIB or IV metastatic breast cancer (MBC)\n* Prior chemotherapy:\n\n  * Phase I: patients must have received prior paclitaxel or other taxanes in either the adjuvant or metastatic setting; prior chemotherapy, radiation or surgery must be completed at least 21 days before study entry; prior treatment with anthracyclines is not required\n  * Phase II: up to two prior chemotherapy regimens for stage IIIB or IV MBC; patients must have received prior paclitaxel or other taxanes in either the adjuvant or metastatic setting; prior chemotherapy, radiation or surgery must be completed at least 21 days before study entry; prior treatment with anthracyclines is not required\n* Measurable disease (phase II)\n* No known brain metastases\n* Hormone receptor status:\n\n  * Not specified\n* Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2\n* White blood cell (WBC) at least 3,000/mm\\^3\n* Absolute neutrophil count at least 1,000/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Hemoglobin at least 9.0 g/dL\n* Bilirubin no greater than 1.5 mg/dL\n* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) no greater than 2.5 times upper limit of normal\n* Creatinine no greater than 1.5 mg/dL\n* Left ventricular ejection fraction (LVEF) at least lower limit of normal\n* No symptomatic congestive heart failure\n* No unstable angina pectoris\n* No cardiac arrhythmia\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No history of allergic reactions attributable to compounds of similar chemical or biological composition to Cremophor\n* No concurrent uncontrolled illness that would preclude study compliance\n* No ongoing or active infection\n* No uncontrolled diabetes mellitus\n* No psychiatric illness or social situations that would preclude study compliance\n* No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* See Disease Characteristics\n* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered\n* No more than 2 prior chemotherapy regimens for this malignancy (phase II)\n* No concurrent steroids or hormones except the following:\n\n  * Steroids to prevent hypersensitivity reactions prior to paclitaxel administration\n  * Hormones for nondisease-related conditions (e.g., insulin for diabetes)\n* At least 3 weeks since prior radiotherapy and recovered\n* At least 3 weeks since prior surgery and recovered\n* No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients\n* No other concurrent investigational agents\n* Concurrent bisphosphonates (i.e., pamidronate or zoledronate) are allowed for the treatment of hypercalcemia or palliation of skeletal metastases",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}